Damora Therapeutics (DMRA) Total Liabilities (2019 - 2026)

Damora Therapeutics has reported Total Liabilities for 8 years, with the latest figure at $23.8 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 1339.55% year-over-year to $23.8 million; the trailing twelve-month figure through Mar 2026 stood at $23.8 million (up 1339.55% YoY), and the FY2025 full-year result was $20.1 million, up 1448.58% from the prior year.
• Total Liabilities for Q1 2026 stood at $23.8 million, up from $20.1 million in the prior quarter.
• The five-year high for Total Liabilities was $23.8 million in Q1 2026, with the low at $1.3 million in Q4 2024.
• Historically, Total Liabilities has averaged $8.6 million across 5 years, with a median of $7.6 million in 2022.
• Annual changes were most pronounced in 2024 — Total Liabilities sank 80.73% — and 2025, when it surged 1448.58%.
• Damora Therapeutics' Total Liabilities stood at $11.4 million in 2022, then plunged by 48.44% to $5.9 million in 2023, then slumped by 77.93% to $1.3 million in 2024, then surged by 1448.58% to $20.1 million in 2025, then increased by 18.33% to $23.8 million in 2026.
• The last three Total Liabilities figures came in at $23.8 million (Q1 2026), $20.1 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.